Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate to severe hidradenitis suppurativa
NCT05819398Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial of spesolimab in hidradenitis suppurativa (HS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percent Change From Baseline in Draining Fistula/Tunnel Count at 8 weeks. Started Apr 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05819398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819398.